Navigation Links
Cholesterol Drugs Might Boost Kidney Cancer Survival
Date:5/7/2013

TUESDAY, May 7 (HealthDay News) -- Cholesterol-lowering statin drugs that are taken by millions of Americans might also improve survival from a type of kidney cancer called renal cell carcinoma, a new study suggests.

Statins -- drugs such as Crestor, Lipitor, Pravachol and Zocor -- have anti-inflammatory and cell self-destruction properties, and previous research has shown that these drugs may lower the risk of developing some types of cancer. The new research, presented Tuesday at the annual meeting of the American Urological Association in San Diego, suggests that the drugs might fight kidney cancer.

"Given that one in four Americans over 45 years of age take a statin and renal cell carcinoma occurs most often in men ages 50 to 70, it may be prudent to prospectively evaluate if statins protect against [cancer] progression," study author Dr. Scott Eggener, an associate professor of urologic oncology at the University of Chicago, said in a meeting press release.

One expert not connected to the study wasn't surprised by the findings.

"The use of statins has shown promise in previous studies with reducing overall cancer-related mortality," said Dr. Michael Palese, an associate professor of urology at the Icahn School of Medicine at Mount Sinai, in New York City. He added that certain characteristics of renal cell carcinomas might render statins "beneficial" for patients.

In the study, Eggener's team reviewed data from more than 900 patients who had surgery for renal cell carcinoma between 1995 and 2010. After an average follow-up period approaching four years, statin use was associated with a reduced risk of cancer progression, the team reported.

Over three years, 10 percent of the patients who took statins died of their cancer, compared with 17 percent of those who did not take this type of drug.

After accounting for other factors, the researchers concluded that statin use was independently associated with both improved overall survival and disease-specific survival.

Another expert said the finding echoes those seen in other studies involving cancer patients.

"Last year in a study published in the New England Journal of Medicine, Danish researchers studied 13 different cancers and found that in all types, the use of statins was associated with longer cancer specific survival," said Dr. Manish Vira, director of the fellowship program in urologic oncology at North Shore-LIJ's Arthur Smith Institute for Urology in Lake Success, N.Y.

But he stressed that the data so far come from observational trials, which can prove an association but not a cause-and-effect relationship between statin use and improved survival.

"Given the current data and known cardiovascular protective effects of statins, certainly it seems prudent to design clinical trials to study the potential of statin therapy in breast, colon, prostate and now kidney cancer treatment," Vira said.

Studies presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

More information

Find out more about renal cell carcinoma at the U.S. National Cancer Institute.

-- Robert Preidt

SOURCES: Michael Palese, M.D., associate professor, urology, Icahn School of Medicine at Mount Sinai, New York City; Manish A. Vira, M.D, director, fellowship program in urologic oncology, North Shore-LIJ Arthur Smith Institute for Urology, Lake Success, N.Y.; American Urological Association, news release, May 7, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Taking cholesterol-lowering drugs may also reduce the risk of dying from prostate cancer: Study
2. Secondhand Smoke Tied to Lower Good Cholesterol in Teen Girls
3. Cholesterol increases risk of Alzheimers and heart disease
4. Commonly used cholesterol calculation underestimates heart disease danger for many
5. UCLA researchers create tomatoes that mimic actions of good cholesterol
6. Cholesterol Levels May Vary By Season
7. New discoveries linking gut bacteria with cholesterol metabolism give hope for the future
8. Jonny Bowden Names 8 Cholesterol Myths, Publishes New Book
9. Overlooked ugly cholesterol causes heart disease
10. Smoking, high blood pressure and cholesterol can be fatal for hemorrhage survivors
11. Cholesterol medicine affects energy production in muscles
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cholesterol Drugs Might Boost Kidney Cancer Survival 
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: